50 results on '"Rosenblat, Joshua D"'
Search Results
2. Immunity as a Common Risk Pathway for Psychiatric and Medical Comorbidity
- Author
-
Rosenblat, Joshua D., McIntyre, Roger S., Berk, Michael, editor, Leboyer, Marion, editor, and Sommer, Iris E., editor
- Published
- 2021
- Full Text
- View/download PDF
3. Association between fatigue and depressive symptoms in persons with post-COVID-19 condition: a post hoc analysis.
- Author
-
Teopiz, Kayla M., Kwan, Angela T. H., Le, Gia Han, Guo, Ziji, Badulescu, Sebastian, Ceban, Felicia, Meshkat, Shakila, Di Vincenzo, Joshua D., d'Andrea, Giacomo, Cao, Bing, Ho, Roger, Rhee, Taeho Greg, Dev, Donovan A., Phan, Lee, Subramaniapillai, Mehala, Mansur, Rodrigo B., Rosenblat, Joshua D., and McIntyre, Roger S.
- Subjects
FATIGUE (Physiology) ,MENTAL depression ,CANCER fatigue ,POST-acute COVID-19 syndrome ,COVID-19 pandemic ,SLEEP interruptions - Abstract
Post-COVID-19 Condition (PCC) is a prevalent, persistent and debilitating phenomenon occurring three or more months after resolution of acute COVID-19 infection. Fatigue and depressive symptoms are commonly reported in PCC. We aimed to further characterize PCC by assessing the relationship between fatigue and depressive symptom severity in adults with PCC. A post hoc analysis was conducted on data retrieved from a randomized, double-blinded, placebo-controlled study evaluating vortioxetine for cognitive deficits in persons with PCC. We sought to determine the relationship between baseline fatigue [i.e. Fatigue Severity Scale (FSS) total score] and baseline depressive symptom severity [i.e. 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR-16) total score] in adults with PCC. The statistical analysis included baseline data from 142 participants. After adjusting for age, sex, education, employment status, history of major depressive disorder (MDD) diagnosis, self-reported physical activity, history of documented acute SARS-CoV-2 infection and body mass index (BMI), baseline FSS was significantly correlated with baseline QIDS-SR-16 (β = 0.825, p =.001) In our sample, baseline measures of fatigue and depressive symptoms are correlated in persons living with PCC. Individuals presenting with PCC and fatigue should be screened for the presence and severity of depressive symptoms. Guideline-concordant care should be prescribed for individuals experiencing clinically significant depressive symptoms. Fatigue and depressive symptom severity scores were not pre-specified as primary objectives of the study. Multiple confounding factors (i.e. disturbance in sleep, anthropometrics and cognitive impairment) were not collected nor adjusted for in the analysis herein. Unrestricted Research Grant from H. Lundbeck A/S, Copenhagen, Denmark. ClinicalTrials.gov Identifier: NCT05047952 [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Strategies to Prolong Ketamine’s Efficacy in Adults with Treatment-Resistant Depression
- Author
-
McMullen, Eric P., Lee, Yena, Lipsitz, Orly, Lui, Leanna M. W., Vinberg, Maj, Ho, Roger, Rodrigues, Nelson B., Rosenblat, Joshua D., Cao, Bing, Gill, Hartej, Teopiz, Kayla M., Cha, Danielle S., and McIntyre, Roger S.
- Published
- 2021
- Full Text
- View/download PDF
5. Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment
- Author
-
Ng, Jason, Lui, Leanna M. W., Rosenblat, Joshua D., Teopiz, Kayla M., Lipsitz, Orly, Cha, Danielle S., Xiong, Jiaqi, Nasri, Flora, Lee, Yena, Kratiuk, Kevin, Rodrigues, Nelson B., Gill, Hartej, Subramaniapillai, Mehala, Mansur, Rodrigo B., Ho, Roger, Cao, Bing, and McIntyre, Roger S.
- Published
- 2021
- Full Text
- View/download PDF
6. Brain-derived neurotrophic factor Val66Met and CYP2B6 polymorphisms as predictors for ketamine effectiveness in patients with treatment-resistant depression.
- Author
-
Rodrigues, Nelson B, Chen-Li, David, Di Vincenzo, Joshua D, Juneja, Ashwin, Pinder, Benjamin D, McIntyre, Roger S, and Rosenblat, Joshua D
- Subjects
BRAIN-derived neurotrophic factor ,KETAMINE ,MENTAL depression ,INTRAVENOUS therapy ,SUICIDAL ideation ,TRANSCRANIAL magnetic stimulation - Abstract
Background: Converging lines of evidence indicate that ketamine is a rapid antidepressant for individuals with treatment-resistant depression. Hitherto, no reliable a priori predictors of ketamine response have been reported. Pharmacogenetic biomarkers have yielded mixed results regarding potential candidate genes associated with ketamine's biochemistry as reliable predictors of response. Aims: No studies have examined the effects of Val66Met and CYP2B6 genotypes on patients receiving repeated infusions of intravenous ketamine. Methods: In all, 85 participants with major depressive disorder who had previously received four infusions of intravenous ketamine were recruited to the foregoing study. Buccal swabs were collected and genotype variants across the Val66Met and CYP2B6 genes were analyzed. A repeated measures mixed linear model was used to assess change in depressive symptoms, suicidality, and anxiety, correcting for sex and age. Multiple regression was run to determine whether these genetic markers were associated with treatment efficacy for depressive severity, suicidal ideation, anxiolytic response, and degree of dissociation to intravenous ketamine. Results: Participants experienced significant overall reductions in depression, suicide, and anxiety. Overall, 25% met the response criteria and 15% met the remission criteria. However, Val66Met and CYP2B6 did not significantly predict changes in symptoms of depression, suicide, anxiety, or average dissociation. Conclusions: This study contributes to the growing literature that ketamine efficacy is unlikely to be predicted by single genes, and a pleiotropic approach may likely be necessary for developing reliable predictors of clinical benefits. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Metabolic-Inflammation Aspects of Depression and Cardiovascular Disease
- Author
-
Rosenblat, Joshua D., Kakar, Ron, McIntyre, Roger S., Baune, Bernhard T., editor, and Tully, Phillip J., editor
- Published
- 2016
- Full Text
- View/download PDF
8. Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth.
- Author
-
Chisamore, Noah, Danayan, Kevork, Rodrigues, Nelson B, Di Vincenzo, Joshua D, Meshkat, Shakila, Doyle, Zoe, Mansur, Rodrigo, Phan, Lee, Fancy, Farhan, Chau, Edmond, Tabassum, Aniqa, Kratiuk, Kevin, Arekapudi, Anil, McIntyre, Roger S, and Rosenblat, Joshua D.
- Subjects
INTRAVENOUS therapy ,GENERALIZED anxiety disorder ,MENTAL depression ,SUICIDAL ideation ,KETAMINE ,OLDER patients - Abstract
Background: Ketamine is an emerging treatment for treatment-resistant depression (TRD) associated with rapid and robust improvements in depressive symptoms and suicidality. However, the efficacy and safety of ketamine in transitional age youth (TAY; age 18–25) populations remains understudied. Methods: In this retrospective analysis, TAY patients (n = 52) receiving ketamine for TRD were matched for sex, primary diagnosis, baseline depression severity, and treatment resistance with a general adult (GA) sample (age 30–60). Patients received four ketamine infusions over 2 weeks (0.5–0.75 mg/kg over 40 min). The primary outcome was the change in Quick Inventory of Depressive Symptomatology Self-Report 16-item (QIDS-SR16) over time. Secondary outcomes were changes in QIDS-SR16 suicidal ideation (SI) item, anxiety (Generalized Anxiety Disorder 7-item (GAD-7)), and adverse effects (ClinicalTrials.gov: NCT04209296). Results: A significant main effect of infusions on reduction of total QIDS-SR16 (p < 0.001), QIDS-SR16 SI (p < 0.001), and GAD-7 (p < 0.001) scores was observed in the TAY group with moderate effect sizes, indicative of clinically significant improvements in depression, anxiety, and suicidality. There were no significant differences between TAY and GA groups on these measures over time, suggesting comparable improvements in both groups. Safety and tolerability outcomes were comparable between groups with only mild, transient adverse effects observed. Conclusion: Ketamine was associated with comparable clinical benefits, safety, and tolerability in a TAY sample as compared to a matched GA TRD sample. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Oral ketamine for depression: An updated systematic review.
- Author
-
Meshkat, Shakila, Haikazian, Sipan, Di Vincenzo, Joshua D., Fancy, Farhan, Johnson, Danica, Chen-Li, David, McIntyre, Roger S., Mansur, Rodrigo, and Rosenblat, Joshua D.
- Subjects
KETAMINE ,EXCITATORY amino acid antagonists ,MENTAL depression ,BIPOLAR disorder - Abstract
Objectives: Ketamine is a glutamate N-methyl-D-aspartate receptor antagonist that can be used to treat major depressive disorder by single or repeated infusions. However, the accessibility and scalability of oral ketamine make it preferred over intravenous ketamine. In this systematic review, we aim to evaluate the efficacy, tolerability, and safety of oral ketamine, esketamine and r-ketamine for unipolar and bipolar depression. Materials and methods: Electronic databases were searched from inception to September 2022 to identify relevant articles. Results: Twenty-two studies, including four randomized clinical trials (RCTs), one case series, six case reports, five open-label trials and six retrospective chart review studies involving 2336 patients with depression were included. All included studies reported significant improvement following ketamine administration. Ketamine was well tolerated without serious adverse events. However, RCTs had a high risk of bias due to analysis methods and adverse events monitoring. Ketamine dosage varied from 0.5 to 1.25 mg/kg. The frequency of administration was daily to monthly. Several important limitations were identified, most notably the small number of RCTs. Conclusions: Taken together, preliminary evidence suggests the potential for antidepressant effect of oral ketamine. However, further research with large sample size and long follow-up period is needed to better determine the antisuicidal effect and efficacy in treatment-resistant depression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Changes in insulin resistance following antidepressant treatment mediate response in major depressive disorder.
- Author
-
Rashidian, Houman, Subramaniapillai, Mehala, Park, Caroline, Lipsitz, Orly, Zuckerman, Hannah, Cao, Bing, Lee, Yena, Gill, Hartej, Rodrigues, Roger Nelson, Di Vincenzo, Joshua D., Iacobucci, Michelle, Jaberi, Saja, Rosenblat, Joshua D., McIntyre, Roger S., and Mansur, Rodrigo B.
- Subjects
ANTIDEPRESSANTS ,MENTAL depression ,INSULIN resistance ,GENERALIZED estimating equations ,BODY mass index ,C-reactive protein - Abstract
Background: Insulin resistance (IR) is a potential predictor of antidepressant treatment response. Aims: We assess changes in IR after antidepressant treatment and whether these changes have any effect on treatment response. Also, to see whether changes in IR mediates relationship between C-reactive protein (CRP) and antidepressant efficacy. Methods: This is a secondary analysis of an 8-week, open-label clinical trial with 95 adults experiencing a major depressive episode. Response to vortioxetine was measured using the Montgomery–Åsberg Depression Rating Scale (MADRS). Generalized estimating equation models were utilized for this intent-to-treat analysis. Results: When adjusted for age, sex, and body mass index, there was a significant increase in IR following treatment in the overall sample (p = 0.035). This finding was detected in treatment non-responders (p = 0.019), whereas it was not observed in responders (p = 0.329). Mediation analysis revealed that change in IR during treatment was responsible for change in MADRS as well as the relationship between baseline CRP and treatment response. Conclusions: Exacerbation of IR during antidepressant treatment mediated non-response. Conversely in treatment responders IR reduced. Like previous studies, baseline CRP moderated treatment response. This relationship was also mediated by changes in IR. These findings further elucidate the role of IR in terms of antidepressant response as well as potentially explain inflammation's relationship with the latter. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Real‐world effectiveness of repeated ketamine infusions for treatment‐resistant bipolar depression.
- Author
-
Fancy, Farhan, Rodrigues, Nelson B., Di Vincenzo, Joshua D., Chau, Edmond H., Sethi, Rickinder, Husain, Muhammad I., Gill, Hartej, Tabassum, Aniqa, Mckenzie, Andrea, Phan, Lee, McIntyre, Roger S., and Rosenblat, Joshua D.
- Subjects
HYPOMANIA ,BIPOLAR disorder ,KETAMINE abuse ,MENTAL depression ,KETAMINE ,SUICIDAL ideation - Abstract
Background: Clinical trials have demonstrated rapid antidepressant effects with intravenous (IV) ketamine for major depressive disorder, with relatively less research specifically for bipolar depression. Herein, we describe the real‐world effectiveness of repeated ketamine infusions for treatment‐resistant bipolar depression. Methods: This study was conducted in a community clinic in Mississauga, Ontario (Canadian Rapid Treatment Centre of Excellence; Braxia Health). In this observational study (NCT04209296), patients with treatment‐resistant bipolar I/II depression (n = 66) received four sub‐anesthetic doses of IV ketamine (0.5–0.75 mg/kg) over a two‐week period. Symptoms of depression, suicidality, anxiety, and functioning were assessed with validated self‐report measures. Results: Statistically and clinically significant antidepressant effects were observed in the overall sample, as measured by the Quick Inventory for Depression Symptomatology‐Self Report‐16 (QIDS‐SR16) with further reductions in depressive symptoms observed after each subsequent infusion (n = 66; mean QIDS‐SR16 reduction of 6.08+/−1.39; p < 0.0001). Significant reductions of suicidal thoughts (QIDS‐SR16‐Suicide Item) and anxiety (Generalized Anxiety Disorder‐7) were also observed with functional improvements on the Sheehan Disability Scale (p < 0.0001 on all measures). Moreover, the response rate (QIDS‐SR16 total score decrease ≥50% from baseline) was 35% and remission rate (QIDS‐SR16 total score ≤5) was 20% after four infusions. Infusions were generally well tolerated with treatment‐emergent hypomania observed in only three patients (4.5%) with zero cases of mania or psychosis. Conclusions: Real‐world effectiveness of IV ketamine for bipolar depression was observed. Repeated doses were associated with greater symptom reduction and adequate tolerability. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. A Phase II, Open-Label Clinical Trial of Intranasal Ketamine for Depression in Patients with Cancer Receiving Palliative Care (INKeD-PC Study).
- Author
-
Rosenblat, Joshua D., deVries, Froukje E., Doyle, Zoe, McIntyre, Roger S., Rodin, Gary, Zimmermann, Camilla, Mak, Ernie, Hannon, Breffni, Schulz-Quach, Christian, Kindy, Aida Al, Patel, Zeal, and Li, Madeline
- Subjects
- *
CANCER patient psychology , *PILOT projects , *ANTIDEPRESSANTS , *CLINICAL trials , *TASTE disorders , *NAUSEA , *LIFE expectancy , *DISSOCIATIVE disorders , *KETAMINE , *INTRANASAL administration , *MENTAL depression , *QUALITY of life , *DESCRIPTIVE statistics , *RESEARCH funding , *FATIGUE (Physiology) , *HEADACHE , *PALLIATIVE treatment , *PATIENT safety , *HALLUCINOGENIC drugs - Abstract
Simple Summary: Ketamine has demonstrated rapid antidepressant effects, but has been minimally studied in cancer populations. We conducted an open-label trial evaluating ketamine for depression in patients with advanced cancer. Participants received three flexible doses of intranasal (IN) ketamine (50–150 mg) over a one-week period. Twenty participants were enrolled in the trial, receiving at least one dose of IN ketamine. We observed rapid, robust and partially sustained antidepressant effects with flexibly dosed IN ketamine with adequate safety and tolerability in individuals with moderate to severe depression comorbid with advanced cancer. Given these promising findings, larger, controlled trials are merited. Antidepressants require several weeks for the onset of action, a lag time that may exceed life expectancy in palliative care. Ketamine has demonstrated rapid antidepressant effects, but has been minimally studied in cancer and palliative care populations. Herein, the objective was to determine the feasibility, safety, tolerability and preliminary efficacy of intranasal racemic ketamine for major depressive disorder (MDD) in patients with advanced cancer. We conducted a single-arm, open-label phase II trial at the Princess Margaret Cancer Centre in Toronto, ON, Canada. Participants with advanced cancer with moderate to severe MDD received three flexible doses of intranasal (IN) ketamine (50–150 mg) over a one-week period. The primary efficacy outcome was an antidepressant response and remission rates as determined by the Montgomery–Åsberg Depression Rating Scale (MADRS) from baseline to the Day 8 primary endpoint. Twenty participants were enrolled in the trial, receiving at least one dose of IN ketamine, with fifteen participants receiving all three doses. The Day 8 antidepressant response (MADRS decreased by >50%) and remission (MADRS < 10 on Day 8) rates were high at 70% and 45%, respectively. Mean MADRS scores decreased significantly from baseline (mean MADRS of 31, standard deviation 7.6) to Day 8 (11 +/− 7.4) with an overall decrease of 20 points (p < 0.001). Antidepressant effects were partially sustained in the second week in the absence of additional ketamine doses, with a Day 14 mean MADRS score of 14 +/− 9.9. Common adverse effects included fatigue, dissociation, nausea, dysgeusia and headaches; almost all adverse effects were mild and transient, resolving within 2 h of each ketamine dose with one dropout related to adverse effects (negative dissociative episode). Given these promising findings, larger, controlled trials are merited. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
- Author
-
Rosenblat, Joshua D., Husain, M. Ishrat, Lee, Yena, McIntyre, Roger S., Mansur, Rodrigo B., Castle, David, Offman, Hilary, Parikh, Sagar V., Frey, Benicio N., Schaffer, Ayal, Greenway, Kyle T., Garel, Nicolas, Beaulieu, Serge, Kennedy, Sidney H., Lam, Raymond W., Milev, Roumen, Ravindran, Arun V., Tourjman, Valerie, Ameringen, Michael Van, and Yatham, Lakshmi N.
- Subjects
- *
MENTAL depression , *TASK forces , *LSD (Drug) , *PSILOCYBIN , *HALLUCINOGENIC drugs , *ANXIETY disorders - Abstract
Objective: Serotonergic psychedelics are re-emerging as potential novel treatments for several psychiatric disorders including major depressive disorder. The Canadian Network for Mood and Anxiety Treatments (CANMAT) convened a task force to review the evidence and provide a consensus recommendation for the clinical use of psychedelic treatments for major depressive disorder. Methods: A systematic review was conducted to identify contemporary clinical trials of serotonergic psychedelics for the treatment of major depressive disorder and cancer-related depression. Studies published between January 1990 and July 2021 were identified using combinations of search terms, inspection of bibliographies and review of other psychedelic reviews and consensus statements. The levels of evidence for efficacy were graded according to the Canadian Network for Mood and Anxiety Treatments criteria. Results: Only psilocybin and ayahuasca have contemporary clinical trials evaluating antidepressant effects. Two pilot studies showed preliminary positive effects of single-dose ayahuasca for treatment-resistant depression (Level 3 evidence). Small randomized controlled trials of psilocybin combined with psychotherapy showed superiority to waitlist controls and comparable efficacy and safety to an active comparator (escitalopram with supportive psychotherapy) in major depressive disorder, with additional randomized controlled trials showing efficacy specifically in cancer-related depression (Level 3 evidence). There was only one open-label trial of psilocybin in treatment-resistant unipolar depression (Level 4 evidence). Small sample sizes and functional unblinding were major limitations in all studies. Adverse events associated with psychedelics, including psychological (e.g., psychotomimetic effects) and physical (e.g., nausea, emesis and headaches) effects, were generally transient. Conclusions: There is currently only low-level evidence to support the efficacy and safety of psychedelics for major depressive disorder. In Canada, as of 2022, psilocybin remains an experimental option that is only available through clinical trials or the special access program. As such, Canadian Network for Mood and Anxiety Treatments considers psilocybin an experimental treatment and recommends its use primarily within clinical trials, or, less commonly, through the special access program in rare, special circumstances. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. Do sleep changes mediate the anti‐depressive and anti‐suicidal response of intravenous ketamine in treatment‐resistant depression?
- Author
-
Rodrigues, Nelson B., McIntyre, Roger S., Lipsitz, Orly, Cha, Danielle S., Cao, Bing, Lee, Yena, Gill, Hartej, Lui, Leanna M. W., Cubała, Wiesław J., Ho, Roger, Shekotikhina, Margarita, Teopiz, Kayla M., Subramaniapillai, Mehala, Kratiuk, Kevin, Mansur, Rodrigo B., and Rosenblat, Joshua D.
- Subjects
KETAMINE ,SLEEP interruptions ,MENTAL depression ,SUICIDAL ideation - Abstract
Summary: Sleep disturbances are commonly reported in patients with treatment‐resistant depression (TRD). Available data have shown that intravenous (IV) ketamine is an effective treatment for patients with TRD and growing data suggest ketamine may improve overall sleep architecture. In the present study, we evaluated whether changes in sleep symptoms mediated the anti‐depressive and/or anti‐suicidal effects of IV ketamine and whether improvement in sleep correlated with a higher likelihood of achieving response or remission. Adults with TRD received four infusions of IV ketamine at a community‐based clinic. Total depressive symptom severity was measured with the Quick Inventory Depressive Symptoms Self‐Report 16‐Item (QIDS‐SR16) at baseline and was repeated across four infusions. Suicidal ideation (SI) and four sleep symptoms were measured using the SI item and the five sleep items on the QIDS‐SR16. A total of 323 patients with TRD received IV ketamine. Self‐reported improvements in insomnia, night‐time restlessness, hypersomnia, early morning waking, and total sleep were significant partial mediators to the improvements observed in depression severity. Similarly, insomnia, night‐time restlessness, early morning waking and total sleep improvements mediated the reduction of IV ketamine on SI. All sleep items, except for hypersomnia, were associated with an increased likelihood of achieving response or remission. Notably, each point improvement in total sleep score was significantly associated with achieving responder/remitter status (odds ratio 3.29, 95% confidence interval 2.00–5.41). Insomnia, sleep restlessness, early morning waking and total sleep improvements were significant mediators of antidepressant and anti‐suicidal improvements in patients with TRD receiving IV ketamine. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series.
- Author
-
Lipsitz, Orly, Di Vincenzo, Joshua D., Rodrigues, Nelson B., Cha, Danielle S., Lee, Yena, Greenberg, David, Teopiz, Kayla M., Ho, Roger C., Cao, Bing, Lin, Kangguang, Subramaniapillai, Mehala, Flint, Alastair J., Kratiuk, Kevin, McIntyre, Roger S., and Rosenblat, Joshua D.
- Abstract
Objective: To evaluate the safety, tolerability, and effectiveness of repeated doses of intravenous (IV) ketamine in older adults (i.e., ≥60 years of age) with treatment-resistant depression.Method: In this case series, fifty-three older adults (Mage = 67, SD = 6; 57% female [n = 30]) received 4 IV ketamine infusions, administered over 1-2 weeks. Effectiveness of IV ketamine was measured using the Quick Inventory for Depressive Symptomatology-Self Report 16 (QIDS-SR16) approximately 2 days after infusions 1-3, and 1-2 weeks after infusion 4. Safety was measured as hemodynamic changes before, during, immediately after, and 20 minutes after each infusion. Tolerability was assessed via systematic reporting of treatment-emergent adverse events during and after each infusion, in addition to symptoms of dissociation measured using the Clinician Administered Dissociative States Scale. Partial response (25%-50% symptomatic improvement from baseline), response (≥50% symptomatic improvement from baseline), clinically significant improvements (≥25% symptomatic improvement from baseline), and remission rates (QIDS-SR16 ≤5) were also calculated.Results: Participants reported significant decreases in depressive symptoms (i.e., as measured by the QIDS-SR16) with repeated ketamine infusions (F(4, 92) = 7.412, p <0.001). The mean QIDS-SR16 score was 17.12 (SD = 5.33) at baseline and decreased to 12.52 (SD = 5.79) following 4 infusions. After 4 infusions, 31% (n = 8) of participants partially responded to IV ketamine, 27% (n = 7) responded, 58% (n = 15) experienced clinically significant improvements, and 10% (n = 3) met remission criteria. Thirty-six participants (69%) experienced treatment-emergent hypertension during at least 1 infusion, and 10 (19%) required intervention with an antihypertensive. Drowsiness was the most commonly reported adverse event (50% of infusions; n = 73).Conclusion: Ketamine was associated with transient treatment-emergent hypertension. Response and remission rates were comparable to those reported in general adult samples. Findings are limited by the open-label, chart review nature of this study. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
16. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
- Author
-
McIntyre, Roger S., Rosenblat, Joshua D., Nemeroff, Charles B., Sanacora, Gerard, Murrough, James W., Berk, Michael, Brietzke, Elisa, Dodd, Seetal, Gorwood, Philip, Ho, Roger, Iosifescu, Dan V., Lopez Jaramillo, Carlos, Kasper, Siegfried, Kratiuk, Kevin, Lee, Jung Goo, Lee, Yena, Lui, Leanna M.W., Mansur, Rodrigo B., Papakostas, George I., and Subramaniapillai, Mehala
- Subjects
- *
KETAMINE , *EXPERT evidence , *MENTAL depression , *KETAMINE abuse , *AFFECTIVE disorders , *ADULTS , *DRUG therapy - Abstract
Replicated international studies have underscored the human and societal costs associated with major depressive disorder. Despite the proven efficacy of monoamine-based antidepressants in major depression, the majority of treated individuals fail to achieve full syndromal and functional recovery with the index and subsequent pharmacological treatments. Ketamine and esketamine represent pharmacologically novel treatment avenues for adults with treatment-resistant depression. In addition to providing hope to affected persons, these agents represent the first non-monoaminergic agents with proven rapid-onset efficacy in major depressive disorder. Nevertheless, concerns remain about the safety and tolerability of ketamine and esketamine in mood disorders. Moreover, there is uncertainty about the appropriate position of these agents in treatment algorithms, their comparative effectiveness, and the appropriate setting, infrastructure, and personnel required for their competent and safe implementation. In this article, an international group of mood disorder experts provides a synthesis of the literature with respect to the efficacy, safety, and tolerability of ketamine and esketamine in adults with treatment-resistant depression. The authors also provide guidance for the implementation of these agents in clinical practice, with particular attention to practice parameters at point of care. Areas of consensus and future research vistas are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
- Author
-
McIntyre, Roger S, Rodrigues, Nelson B, Lipsitz, Orly, Nasri, Flora, Gill, Hartej, Lui, Leanna MW, Subramaniapillai, Mehala, Kratiuk, Kevin, Teopiz, Kayla, Ho, Roger, Lee, Yena, Mansur, Rodrigo B, and Rosenblat, Joshua D
- Subjects
MENTAL depression ,BIPOLAR disorder ,SEPARATION anxiety ,ANXIETY ,GENERALIZED anxiety disorder ,KETAMINE ,ADULTS - Abstract
Background: Individuals meeting criteria for treatment-resistant depression (TRD) are differentially affected by high levels of anxiety symptoms. Aims: There is a need to identify the efficacy of novel rapid-onset treatments in adults with mood disorders and comorbid anxious-distress. Methods: This study included patients with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD) who were receiving intravenous (IV) ketamine treatment at a community-based clinic.Anxious-distress was proxied using items from the Quick Inventory of Depressive Symptomatology–Self Report 16-item (QIDS-SR
16 ) and Generalized Anxiety Disorder 7-item (GAD7) scales. The difference in QIDS-SR16 total score, QIDS-SR16 suicidal ideation (SI) item and GAD7 score were analyzed between groups. Results: A total of 209 adults with MDD (n = 177) and BD (n = 26) were included in this analysis. From this sample, 94 patients (mean = 45 ± 13.9 years) met the criteria for anxious-distress. Individuals meeting the criteria for anxious-distress exhibited a significantly greater reduction in QIDS-SR16 total score following four infusions (p = 0.02) when compared with patients not meeting the anxious-distress criteria. Both anxious-distressed and low-anxiety patients exhibited a significant reduction in SI (p < 0.0001) following four infusions.Finally, there was a significantly greater reduction in anxiety symptoms in the anxious-distress group compared with the non–anxious distress group following three (p = 0.02) and four infusions (p < 0.001). Conclusion: Patients with TRD and prominent anxiety receiving IV ketamine exhibited a significant reduction in depressive, SI and anxiety symptoms. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
18. The THINC-it Tool for Cognitive Assessment and Measurement in Major Depressive Disorder: Sensitivity to Change.
- Author
-
McIntyre, Roger S., Subramaniapillai, Mehala, Park, Caroline, Zuckerman, Hannah, Cao, Bing, Lee, Yena, Iacobucci, Michelle, Nasri, Flora, Fus, Dominika, Bowie, Christopher R., Tran, Tanya, Rosenblat, Joshua D., and Mansur, Rodrigo B.
- Subjects
MENTAL depression ,COGNITIVE testing ,CLINICAL trial registries ,SHORT-term memory ,MEASURING instruments - Abstract
Background: Herein, we sought to determine the sensitivity to change in cognitive function, as measured by the THINC-it tool, in a sample of adults with major depressive disorder (MDD) receiving standardized antidepressant therapy. Methods: Adults meeting the DSM-5 criteria for MDD with at least moderate depressive symptom severity [ i.e. , Montgomery Åsberg Depression Rating Scale (MADRS) total score ≥ 20] were treated with open-label vortioxetine (10–20 mg/day, flexibly-dosed) for 8 weeks. The previously validated THINC-it tool was the primary dependent measure. The THINC-it tool was validated against the paper and pencil version of the Digit Symbol Substitution Test (DSST) and the Trails Making Test B (TMTB). Results: After 8 weeks of treatment, adults with MDD exhibited improvement in cognitive function relative to healthy controls (e.g. , processing speed) (p = 0.031). A subdomain measure of working memory (i.e. , symbol check; SC) exhibited significant improvement at Weeks 2 and 8 in latency (p = 0.032), SC accuracy (p = 0.046), and objective z-score (p = 0.001) independent of depressive symptoms. A linear regression analysis determined that the THINC-it tool measures of processing speed, as well as executive function were significantly associated with changes observed on the pencil and paper version the Digit Symbol Substitution Test (DSST) (p = 0.002) and in Trails Making Test B (TMTB) (p = 0.003), respectively. Conclusion: The THINC-it tool demonstrates sensitivity to change in adults with MDD and is highly correlated with improvements on pencil and paper versions of DSST and TMTB. Clinical Trial Registration: ClinicalTrials.gov, identifier NCT03053362. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. Depression in the medically ill.
- Author
-
Rosenblat, Joshua D, Kurdyak, Paul, Cosci, Fiammetta, Berk, Michael, Maes, Michael, Brunoni, Andre R, Li, Madeline, Rodin, Gary, McIntyre, Roger S, and Carvalho, Andre F
- Subjects
- *
DIAGNOSIS of mental depression , *ADJUSTMENT disorders , *ANTIDEPRESSANTS , *CHRONIC diseases , *MENTAL depression , *DIFFERENTIAL diagnosis , *DRUG interactions , *MEDICAL screening , *PSYCHOTHERAPY , *PSYCHOEDUCATION - Abstract
Background: Depressive disorders are significantly more common in the medically ill compared to the general population. Depression is associated with worsening of physical symptoms, greater healthcare utilization and poorer treatment adherence. The present paper provides a critical review on the assessment and management of depression in the medically ill. Methods: Relevant articles pertaining to depression in the medically ill were identified, reviewed and synthesized qualitatively. A systematic review was not performed due to the large breadth of this topic, making a meaningful summary of all published and unpublished studies not feasible. Notable studies were reviewed and synthesized by a diverse set of experts to provide a balanced summary. Results: Depression is frequently under-recognized in medical settings. Differential diagnoses include delirium, personality disorders and depressive disorders secondary to substances, medications or another medical condition. Depressive symptoms in the context of an adjustment disorder should be initially managed by supportive psychological approaches. Once a mild to moderate major depressive episode is identified, a stepped care approach should be implemented, starting with general psychoeducation, psychosocial interventions and ongoing monitoring. For moderate to severe symptoms, or mild symptoms that are not responding to low-intensity interventions, the use of antidepressants or higher intensity psychotherapeutic interventions should be considered. Psychotherapeutic interventions have demonstrated benefits with small to moderate effect sizes. Antidepressant medications have also demonstrated benefits with moderate effect sizes; however, special caution is needed in evaluating side effects, drug–drug interactions as well as dose adjustments due to impairment in hepatic metabolism and/or renal clearance. Novel interventions for the treatment of depression and other illness-related psychological symptoms (e.g. death anxiety, loss of dignity) are under investigation. Limitations: Non-systematic review of the literature. Conclusion: Replicated evidence has demonstrated a bidirectional interaction between depression and medical illness. Screening and stepped care using pharmacological and non-pharmacological interventions is merited. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. Changes in sleep predict changes in depressive symptoms in depressed subjects receiving vortioxetine: An open-label clinical trial.
- Author
-
Cao, Bing, Park, Caroline, Rosenblat, Joshua D, Chen, Yan, Iacobucci, Michelle, Subramaniapillai, Mehala, Mansur, Rodrigo B, Zuckerman, Hannah, Lee, Yena, and McIntyre, Roger S
- Subjects
DRUG labeling ,MENTAL depression ,EPWORTH Sleepiness Scale ,CLINICAL trials ,MENTAL illness ,ANTIDEPRESSANTS ,RESEARCH ,RESEARCH methodology ,CASE-control method ,EVALUATION research ,MEDICAL cooperation ,SLEEP ,SEVERITY of illness index ,COMPARATIVE studies - Abstract
Background: Sleep disturbances are frequently reported in patients with major depressive disorder. We aimed to investigate the effects of vortioxetine on sleep quality and association between changes in sleep and treatment response.Methods: This study is a post-hoc analysis of a clinical trial that sought to evaluate the sensitivity to cognitive change of THINC-integrated tool in patients with major depressive disorder. In total, 92 patients (aged 18 to 65) meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for moderate or severe major depressive disorder and 54 healthy controls were included. All patients received open-label vortioxetine (10-20 mg/day, flexibly dosed) for 8 weeks. Herein, the primary outcomes of interest were changes in sleep, as measured by the Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale and Insomnia Severity Index, between weeks 0, 2, and 8. The association between changes in sleep and depressive symptom severity was secondarily assessed.Results: We observed that sleep, as indicated by scores of Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale and Insomnia Severity Index, was significantly poorer in patients with major depressive disorder compared to healthy controls at weeks 0, 2, and 8 (p < 0.05). Among patients with major depressive disorder, we observed significant improvements on the Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale and Insomnia Severity Index between weeks 0 and 8 (p < 0.05). We observed a significant association between improvements on the Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, and Insomnia Severity Index and improvement of depressive symptoms.Conclusion: Improvement of depressive symptoms in major depressive disorder patients treated with vortioxetine was associated with significant improvements in sleep. Furthermore, improvements in sleep were predictive of antidepressant response and were linearly correlated with improvement in overall depressive symptom severity. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
21. Stress, epigenetics and depression: A systematic review.
- Author
-
Park, Caroline, Rosenblat, Joshua D., Brietzke, Elisa, Pan, Zihang, Lee, Yena, Cao, Bing, Zuckerman, Hannah, Kalantarova, Anastasia, and McIntyre, Roger S.
- Subjects
- *
META-analysis , *DNA structure , *GENE expression , *DNA methylation - Abstract
• Childhood maltreatment is an important stressor associated with stress & depression. • Stress- and depression-associated changes were mostly found in NRC31 and SLCA4. • Epigenetic changes occurring at different loci may have variable downstream effects. • Most studies measured epigenetic changes using peripheral tissue samples. • Future studies should evaluate epigenetic effects of psychotropic medication use. Environmental stressors, such as childhood maltreatment, have been recognized to contribute to the development of depression. Growing evidence suggests that epigenetic changes are a key mechanism by which stressors interact with the genome leading to stable changes in DNA structure, gene expression, and behaviour. The current review aimed to evaluate the relationship between stress-associated epigenetic changes and depression. Human studies were identified via systematic searching of PubMed/Medline from inception to February 2018. Seventeen articles were identified. Stress-associated epigenetic changes in the following genes were correlated with depression: NRC31, SLCA4, BDNF, FKBP5, SKA2, OXTR , LINGO3, POU3F1 and ITGB1. Epigenetic changes in glucocorticoid signaling (e.g., NR3C1, FKBP5), serotonergic signaling (e.g. SLC6A4), and neurotrophin (e.g., BDNF) genes appear to be the most promising therapeutic targets for future research. However, continued research is warranted due to inconsistent findings regarding the directionality of epigenetic modification. Future studies should also aim to control for the use of psychotropic agents due to their widespread use in depressed populations and established effects on DNA methylation. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
22. Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review.
- Author
-
Shariq, Aisha S., Rosenblat, Joshua D., Alageel, Asem, Mansur, Rodrigo B., Rong, Carola, Ho, Roger C., Ragguett, Renee-Marie, Pan, Zihang, Brietzke, Elisa, and McIntyre, Roger S.
- Subjects
- *
OREXINS , *APPETITE , *THERAPEUTICS , *SLEEP-wake cycle , *MENTAL depression , *AFFECTIVE disorders , *NEUROPEPTIDES - Abstract
Orexins are neuropeptides that are postulated to play a central role in the regulation of the sleep-wake cycle, appetite, affect, and reward circuitry. The objectives of the current review are to comprehensively evaluate (1) the potential role of orexins in the pathophysiology of major depressive disorders (MDD) and (2) the orexin system as a novel target in the treatment of MDD. Dysfunction of the sleep-wake cycle is observed as a central feature of MDD pathophysiology. Orexin system disturbances produce sleep-wake dysfunction, as observed in MDD. Orexin antagonists have been shown to treat insomnia effectively without disrupting normal sleep architecture in both preclinical (e.g., animal models) and clinical studies. Orexin antagonists are generally safe, well-tolerated, and associated with an acceptable long-term adverse effect profile with relatively low propensity for tolerance or dependence. Orexin antagonists have also been shown to possess antidepressant-like properties in some animal models of MDD. Extant evidence indicates that orexin-modulating treatments exert pleiotropic effects on multiple neural systems implicated in the phenomenology of mood disorders and suggests orexins as a promising target for investigation and intervention in mood disorders. To date, no human clinical trials evaluating the antidepressant effects of orexin antagonists in MDD have been completed. Given the promising results from preclinical studies, clinical trials are merited to evaluate the antidepressant effects of orexin antagonists in MDD. • Orexins are neuropeptides that are postulated to play a central role in the regulation of the sleep-wake cycle, appetite, affect, and reward circuitry • Dysfunction of the sleep-wake cycle is observed as a central feature of MDD pathophysiology • Orexin system disturbances produce sleep-wake dysfunction, as observed in MDD • Orexin antagonists are generally safe, well-tolerated, and associated with an acceptable long-term adverse effect profile with relatively low propensity for tolerance or dependence and has shown to possess antidepressant properties • The objectives are to evaluate (1) the potential role of orexins in the pathophysiology of major depressive disorders (MDD) and (2) the orexin system as a novel target in the treatment of MDD [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
23. Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression.
- Author
-
Rosenblat, Joshua D., Simon, Gregory E., Sachs, Gary S., Deetz, Ingrid, Doederlein, Allen, DePeralta, Denisse, Dean, Mary Mischka, and McIntyre, Roger S.
- Subjects
- *
DRUG efficacy , *BIPOLAR disorder , *MENTAL depression , *WEIGHT gain , *CLINICAL trials , *PSYCHIATRIC drugs , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *QUALITY of life , *RESEARCH , *SELF-evaluation , *EVALUATION research , *TREATMENT effectiveness , *PSYCHOLOGY - Abstract
Objective: To evaluate patient-reported determinants of treatment effectiveness and tolerability amongst persons with major depressive or bipolar disorders.Methods: The Depression and Bipolar Support Alliance (DBSA) conducted an online survey February 2016-April 2016 asking participants about which outcomes are most important in determining subjective treatment effectiveness and tolerability.Results: In total, 896 participants completed the survey [49.9% unipolar depression (n = 447) and 50.1% bipolar depression (n = 449)]. Survey respondents reported several previous medication trials with the minority (25% of depression and 29% of bipolar group) of respondents reporting that their current treatment plan was completely effective. When asked how they know that the treatment is working, for both groups, the highest rated response was, "I don't feel overly anxious, agitated or irritable." Weight gain was the adverse effect that most commonly led respondents to discontinue a medication. Lethargy, emotional blunting, shaking/trembling and anxiety were also identified as common treatment-emergent experiences leading to medication discontinuation in greater than one-third of respondents. The bipolar group more frequently identified several signs that suggested treatment was working (e.g., improved neurocognitive function, improved sleep), as well as more frequently reported several reasons to discontinue medications (e.g., weight gain, trembling).Conclusion: Numerous factors emerged as important to patients when evaluating treatment effectiveness and tolerability. Some of these factors are inadequately assessed by current standard clinical trial outcome measures. Considering these important patient-centred outcomes in future clinical trials, treatment guidelines and direct patient care may serve to improve patient satisfaction, quality of life and the therapeutic alliance. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
24. Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials.
- Author
-
Rosenblat, Joshua D. and McIntyre, Roger S.
- Subjects
- *
MINOCYCLINE , *ANTIDEPRESSANTS , *MENTAL depression , *THERAPEUTICS , *PLACEBOS , *RANDOMIZED controlled trials , *META-analysis , *SYSTEMATIC reviews - Abstract
Background: Minocycline has been identified as a potential novel treatment for depression. The objective of the current review is to determine the overall antidepressant efficacy and tolerability of minocycline.Methods: Completed and ongoing clinical trials of minocycline for depression (both bipolar and unipolar) published prior to September 12, 2017 were identified through searching relevant databases. Using a random-effects model, data from randomized controlled trials (RCTs) were pooled to determine the antidepressant effect size of minocycline compared to placebo. Relative risk of all-cause discontinuation was determined to assess overall tolerability.Results: Eighteen clinical studies (including published and unpublished RCTs, open label studies, ongoing clinical trials and a case report) were identified for inclusion in the qualitative synthesis. Only three RCTs (n = 158) met inclusion criteria for quantitative synthesis. The overall antidepressant effect size of minocycline compared to placebo was - 0.78 [95% confidence interval - 0.4 to - 1.33 (P = 0.005)], indicative of a large and statistically significant antidepressant effect. Heterogeneity of the pooled sample was moderate (I2 = 62%). There was no statistically significant difference in reported adverse effects or all-cause discontinuation in the minocycline group compared to placebo (p = 0.16).Limitations: The small number of published RCTs, small sample sizes, heterogeneity of included studies, and potential publication bias were significant limitations.Conclusions: Overall, a large antidepressant effect was observed for minocycline compared to placebo with good tolerability. The current analysis provides a proof-of-concept for the antidepressant effects of minocycline and provides impetus for future larger RCTs as well as identification of subgroups more likely to benefit from this intervention. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
25. Pain and major depressive disorder: Associations with cognitive impairment as measured by the THINC-integrated tool (THINC-it).
- Author
-
Cha, Danielle S., Carmona, Nicole E., Mansur, Rodrigo B., Lee, Yena, Park, Hyun Jung, Rodrigues, Nelson B., Subramaniapillai, Mehala, Rosenblat, Joshua D., Pan, Zihang, Lee, Jae Hon, Lee, JungGoo, Almatham, Fahad, Alageel, Asem, Shekotikhina, Margarita, Zhou, Aileen J., Rong, Carola, Harrison, John, and McIntyre, Roger S.
- Abstract
Objectives To examine the role of pain on cognitive function in adults with major depressive disorder (MDD). Methods Adults (18–65) with a Diagnostic and Statistical Manual – Fifth Edition (DSM-5)-defined diagnosis of MDD experiencing a current major depressive episode (MDE) were enrolled ( n MDD = 100). All subjects with MDD were matched in age, sex, and years of education to healthy controls (HC) ( n HC = 100) for comparison. Cognitive function was assessed using the recently validated THINC-integrated tool (THINC-it), which comprises variants of the choice reaction time (i.e., THINC-it: Spotter ), One-Back (i.e., THINC-it: Symbol Check ), Digit Symbol Substitution Test (i.e., THINC-it: Codebreaker ), Trail Making Test – Part B (i.e., THINC-it: Trails ), as well as the Perceived Deficits Questionnaire for Depression – 5-item (i.e., THINC-it: PDQ-5-D ). A global index of objective cognitive function was computed using objective measures from the THINC-it, while self-rated cognitive deficits were measured using the PDQ-5-D. Pain was measured using a Visual Analogue Scale (VAS). Regression analyses evaluated the role of pain in predicting objective and subjective cognitive function. Results A significant between-group differences on the VAS was observed ( p < 0.001), with individuals with MDD reporting higher pain severity as evidenced by higher scores on the VAS than HC. Significant interaction effects were observed between self -rated cognitive deficits and pain ratings ( p < 0.001) on objective cognitive performance (after adjusting for MADRS total score), suggesting that pain moderates the association between self-rated and objective cognitive function. Conclusions Results indicated that pain is associated with increased self-rated and objective cognitive deficits in adults with MDD. Implications The study herein provides preliminary evidence demonstrating that adults with MDD reporting pain symptomatology and poorer subjective cognitive function is predictive of poorer objective cognitive performance. THINC-it is capable of detecting cognitive dysfunction amongst adults with MDD and pain. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
26. The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta- Analysis of Randomized Clinical Trials.
- Author
-
Rosenblat, Joshua D., Kakar, Ron, and McIntyre, Roger S.
- Subjects
ANTIDEPRESSANTS ,COGNITIVE analysis ,MENTAL depression ,CLINICAL trials ,META-analysis - Abstract
Background: Cognitive dysfunction is often present in major depressive disorder (MDD). Several clinical trials have noted a pro-cognitive effect of antidepressants in MDD. The objective of the current systematic review and meta-analysis was to assess the pooled efficacy of antidepressants on various domains of cognition in MDD. Methods: Trials published prior to April 15, 2015, were identified through searching the Cochrane Central Register of Controlled Trials, PubMed, Embase, PsychINFO, Clinicaltrials.gov, and relevant review articles. Data from randomized clinical trials assessing the cognitive effects of antidepressants were pooled to determine standard mean differences (SMD) using a random-effects model. Results: Nine placebo-controlled randomized trials (2 550 participants) evaluating the cognitive effects of vortioxetine (n = 728), duloxetine (n = 714), paroxetine (n = 23), citalopram (n = 84), phenelzine (n = 28), nortryptiline (n = 32), and sertraline (n = 49) were identified. Antidepressants had a positive effect on psychomotor speed (SMD 0.16; 95% confidence interval [CI] 0.05-0.27; I2 = 46%) and delayed recall (SMD 0.24; 95% CI 0.15-0.34; I2 = 0%). The effect on cognitive control and executive function did not reach statistical significance. Of note, after removal of vortioxetine from the analysis, statistical significance was lost for psychomotor speed. Eight head-to-head randomized trials comparing the effects of selective serotonin reuptake inhibitors (SSRIs; n = 371), selective serotonin and norepinephrine reuptake inhibitors (SNRIs; n = 25), tricyclic antidepressants (TCAs; n = 138), and norepinephrine and dopamine reuptake inhibitors (NDRIs; n = 46) were identified. No statistically significant difference in cognitive effects was found when pooling results from head-to-head trials of SSRIs, SNRIs, TCAs, and NDRIs. Significant limitations were the heterogeneity of results, limited number of studies, and small sample sizes. Conclusions: Available evidence suggests that antidepressants have a significant positive effect on psychomotor speed and delayed recall. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
27. Inflamed moods: A review of the interactions between inflammation and mood disorders.
- Author
-
Rosenblat, Joshua D., Cha, Danielle S., Mansur, Rodrigo B., and McIntyre, Roger S.
- Subjects
- *
INFLAMMATION treatment , *MENTAL health services , *AFFECTIVE disorders , *PATHOLOGICAL physiology , *COGNITION disorders , *BIPOLAR disorder , *CYTOKINES - Abstract
Abstract: Mood disorders have been recognized by the World Health Organization (WHO) as the leading cause of disability worldwide. Notwithstanding the established efficacy of conventional mood agents, many treated individuals continue to remain treatment refractory and/or exhibit clinically significant residual symptoms, cognitive dysfunction, and psychosocial impairment. Therefore, a priority research and clinical agenda is to identify pathophysiological mechanisms subserving mood disorders to improve therapeutic efficacy. During the past decade, inflammation has been revisited as an important etiologic factor of mood disorders. Therefore, the purpose of this synthetic review is threefold: 1) to review the evidence for an association between inflammation and mood disorders, 2) to discuss potential pathophysiologic mechanisms that may explain this association and 3) to present novel therapeutic options currently being investigated that target the inflammatory–mood pathway. Accumulating evidence implicates inflammation as a critical mediator in the pathophysiology of mood disorders. Indeed, elevated levels of pro-inflammatory cytokines have been repeatedly demonstrated in both major depressive disorder (MDD) and bipolar disorder (BD) patients. Further, the induction of a pro-inflammatory state in healthy or medically ill subjects induces ‘sickness behavior’ resembling depressive symptomatology. Potential mechanisms involved include, but are not limited to, direct effects of pro-inflammatory cytokines on monoamine levels, dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, pathologic microglial cell activation, impaired neuroplasticity and structural and functional brain changes. Anti-inflammatory agents, such as acetyl-salicylic acid (ASA), celecoxib, anti-TNF-α agents, minocycline, curcumin and omega-3 fatty acids, are being investigated for use in mood disorders. Current evidence shows improved outcomes in mood disorder patients when anti-inflammatory agents are used as an adjunct to conventional therapy; however, further research is needed to establish the therapeutic benefit and appropriate dosage. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
28. Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysis.
- Author
-
Wong, Sabrina, Le, Gia Han, Phan, Lee, Rhee, Taeho Greg, Ho, Roger, Meshkat, Shakila, Teopiz, Kayla M., Kwan, Angela T.H., Mansur, Rodrigo B., Rosenblat, Joshua D., and McIntyre, Roger S.
- Subjects
- *
MENTAL depression , *ANHEDONIA , *QUALITY of life , *FUNCTIONAL status , *RANDOM effects model - Abstract
Major depressive disorder (MDD) is a heterogeneous group of mood disorders. A prominent symptom domain is anhedonia narrowly defined as a loss of interest and ability to experience pleasure. Anhedonia is associated with depressive symptom severity, MDD prognosis, and suicidality. We perform a systematic review and meta-analysis of extant literature investigating the effects of anhedonia on health-related quality of life (HRQoL) and functional outcomes in persons with MDD. A literature search was conducted on PubMed, OVID databases, and SCOPUS for published articles from inception to November 2023, reporting on anhedonia and patient-reported outcomes in persons with MDD. The reported correlation coefficients between anhedonia and self-reported measures of both HRQoL and functional outcomes were pooled using a random effects model. We identified 20 studies that investigated anhedonia with HRQoL and/or functional outcomes in MDD. Anhedonia as measured by the Snaith-Hamilton Pleasure Scale (SHAPS) scores had a statistically significant correlation with patient-reported HRQoL (r = −0.41 [95 % CI = −0.60, −0.18]) and functional impairment (r = 0.39 [95 % CI = 0.22, 0.54]). These preliminary results primarily investigate correlations with consummatory anhedonia and do not distinguish differences in anticipatory anhedonia, reward valuation or reward learning; therefore, these results require replication. Persons with MDD experiencing symptoms of anhedonia are more likely to have worse prognosis including physical, psychological, and social functioning deficits. Anhedonia serves as an important predictor and target for future therapeutic and preventative tools in persons with MDD. • Anhedonia is significantly correlated with a decreased HRQoL in MDD persons. • Anhedonia is significantly correlated with functional impairment in MDD persons. • Anhedonia serves as a primary target for future MDD therapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder.
- Author
-
Meshkat, Shakila, Teopiz, Kayla M., Di Vincenzo, Joshua D., Bailey, Julia B., Rosenblat, Joshua D., Ho, Roger C., Rhee, Taeho Greg, Ceban, Felicia, Kwan, Angela T.H., Cao, Bing, and McIntyre, Roger S.
- Subjects
- *
MENTAL depression , *POSTPARTUM depression , *BIPOLAR disorder , *GABA , *MENTAL illness , *VENLAFAXINE - Abstract
Major depressive disorder (MDD) is a common mental disorder with a high rate of morbidity and mortality. Dysfunctional signaling of gamma-aminobutyric acid (GABA) has been implicated in some studies in the etiology of MDD. Zuranolone (SAGE-217) is a novel, oral neuroactive steroid and an investigational positive allosteric modulator of synaptic and extrasynaptic GABAA receptors. Herein, we aimed to evaluate the efficacy and safety of Zuranolone in individuals with MDD. We reviewed seven studies including 1662 participants with MDD. Zuranolone was investigated as an oral, once-daily, 14-day treatment course. The results of our synthesis indicate that the antidepressant effects of Zuranolone are rapid, clinically meaningful, and replicated across multiple randomized clinical trials. In addition to replicated efficacy, Zuranolone is associated with an acceptable level of treatment-emergent adverse events and discontinuation without serious adverse events. It is believed that Zuranolone's antidepressant effects arise from its ability to enhance inhibitory GABAergic signaling by increasing synaptic and extrasynaptic GABAA activity and regulation of GABAA receptor expression. Taken together, preliminary evidence suggests the potential for antidepressant effects of Zuranolone. Zuranolone has been approved by FDA for postpartum depression, and is showing efficacy in major depressive disorder. Future research vistas should seek to determine the durability of this treatment approach as well as its effects on domain-specific outcomes (e.g., anhedonia, circadian rhythm, arousal systems) along with application in other diagnostic entities (e.g., bipolar depression). • Zuranolone is a PAM of the GABAA receptor that binds to extrasynaptic and synaptic GABAA receptors. • The rapid antidepressant effect of Zuranolone is an advantage over traditional treatments. • Zuranolone is effective in treatment of MDD and postpartum depression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
30. Probiotics for the treatment of depressive symptoms: An anti-inflammatory mechanism?
- Author
-
Park, Caroline, Brietzke, Elisa, Rosenblat, Joshua D., Musial, Natalie, Zuckerman, Hannah, Ragguett, Renee-Marie, Pan, Zihang, Rong, Carola, Fus, Dominika, and McIntyre, Roger S.
- Subjects
- *
PROBIOTICS , *PREVENTION of mental depression , *ANTI-inflammatory agents , *GUT microbiome , *ANTIDEPRESSANTS , *SEROTONIN uptake inhibitors - Abstract
Highlights • Numerous studies indicate that probiotics have anti-inflammatory effects. • Immune-inflammatory modulation may mediate the antidepressant effects of probiotics. • Probiotics may be more effective in depressed subgroups with elevated inflammation. • Future studies should parse out the heterogeneous effects of different probiotics. Abstract During the past decade, there has been renewed interest in the relationship between brain-based disorders, the gut microbiota, and the possible beneficial effects of probiotics. Emerging evidence suggests that modifying the composition of the gut microbiota via probiotic supplementation may be a viable adjuvant treatment option for individuals with major depressive disorder (MDD). Convergent evidence indicates that persistent low-grade inflammatory activation is associated with the diagnosis of MDD as well as the severity of depressive symptoms and probability of treatment response. The objectives of this review are to (1) evaluate the evidence supporting an anti-inflammatory effect of probiotics and (2) describe immune system modulation as a potential mechanism for the therapeutic effects of probiotics in populations with MDD. A narrative review of studies investigating the effects of probiotics on systemic inflammation was conducted. Studies were identified using PubMed/Medline, Google Scholar, and clinicaltrials.gov (from inception to November 2017) using the following search terms (and/or variants): probiotic , inflammation , gut microbiota , and depression. The available evidence suggests that probiotics should be considered a promising adjuvant treatment to reduce the inflammatory activation commonly found in MDD. Several controversial points remain to be addressed including the role of leaky gut, the role of stress exposure, and the role of blood-brain-barrier permeability. Taken together, the results of this review suggest that probiotics may be a potentially beneficial, but insufficiently studied, antidepressant treatment intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
31. The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine.
- Author
-
McIntyre, Roger S., Lipsitz, Orly, Lui, Leanna M.W., Rodrigues, Nelson B., Gill, Hartej, Nasri, Flora, Ling, Rui, Teopiz, Kayla M., Ho, Roger C., Subramaniapillai, Mehala, Kratiuk, Kevin, Mansur, Rodrigo B., Jones, Brett D.M., Lee, Yena, and Rosenblat, Joshua D.
- Subjects
- *
MENTAL depression , *ADULTS , *HYPOMANIA , *KETAMINE abuse , *KETAMINE , *MEDICAL personnel , *SYMPTOMS , *RESEARCH , *SELF-evaluation , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *PSYCHOLOGICAL tests , *COMPARATIVE studies , *QUESTIONNAIRES , *BIPOLAR disorder - Abstract
Objective: .To identify a meaningful change threshold (MCT) in depression outcomes in adults with treatment-resistant major depressive disorder (MDD) or bipolar disorder (BD) receiving intravenous ketamine treatment at a community-based mood disorders center.Method: .A triangular approach integrating both anchor-based and distributive methods was used to identify meaningful change on the patient-reported Quick Inventory for Depressive Symptoms Self-Report 16-Item (QIDS-SR16) as associated with the Patient Global Impression - Severity (PGI-S). Both the QIDS-SR16 and the PGI-S are self-report measures, and were collected at five timepoints (timepoints were approximately 2-7 days apart).Results: .A total of 297 adults with treatment-resistant depression (TRD) as part of either DSM-5-defined MDD or BD were included. The MCT for the QIDS-SR16 revealed that a mean improvement of 3.38 points from baseline was comparable to a 1-point improvement on the PGI-S. Together with an examination of the probability density function, a 3.5-point change is a reasonable MCT (i.e., 1-point PGI-S improvement) for the QIDS-SR16. A 2-point symptomatic improvement on the QIDS-SR16 was associated with no change on the PGI-S.Conclusion: .A 3.5-point reduction in the QIDS-SR16 represents a MCT based on the PGI-S for adults with treatment-resistant MDD or BD receiving intravenous ketamine treatment at a community-based mood disorders center. These findings are limited by the post-hoc nature of this analysis and open-label case-series design. Measurement-based care decisions by patients, providers and clinicians, as well as cost/reimbursement decisions should include consideration of meaningful change along with conventional objective outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
32. Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?
- Author
-
McIntyre, Roger S, Lipsitz, Orly, Lui, Leanna M W, Rodrigues, Nelson B, Lee, Yena, Ho, Roger C, Subramaniapillai, Mehala, Gill, Hartej, Cha, Danielle S, Lin, Kangguang, Teopiz, Kayla M, Nasri, Flora, Mansur, Rodrigo B, Kratiuk, Kevin, and Rosenblat, Joshua D
- Subjects
- *
ADULTS , *KETAMINE , *MENTAL depression , *BIPOLAR disorder , *DISABILITIES - Abstract
Background: The efficacy of monoamine-based antidepressants in adults with major depressive disorder (MDD) is attenuated in persons with greater pre-treatment functional impairment. Herein, we investigated whether pre-treatment functioning in outpatients with treatment-resistant depression (TRD) moderates response to intravenous (IV) ketamine.Methods: Adults (N= 326; Mage = 45) with DSM-5-defined MDD or bipolar disorder and TRD received repeat-dose IV ketamine at a community-based clinic. Function was evaluated with the Sheehan Disability Scale (SDS), using total scores as well as scores on the subdomains of workplace/school, social life, and family life/home responsibilities. The primary dependent measure was change in depressive symptoms from pre-treatment to post-infusion 4, as measured by the Quick Inventory for Depressive Symptomatology-Self Report-16.Results: Total functional disability, as well as the subdomains of social life and family life/home responsibilities, significantly moderated response to IV ketamine (p = .003; p = .008; p = .008). Follow-up simple slopes analyses indicated a significant improvement in depressive symptoms across the functional domain spectrum (ps < .001). Above average functional disability (i.e., 1 SD > mean functional impairment within the sample) was associated with a greater change in depressive symptoms. Workplace function did not significantly moderate response to IV ketamine (p = .307), suggesting that individuals with significantly impaired workplace functioning may expect a similar response to ketamine as those with less workplace impairment.Conclusions: Symptomatic benefit with IV ketamine was observed in patients with TRD and significant pre-treatment functional impairment. The foregoing result has implications for mechanism of action, cost-effectiveness, and patient selection in adults with TRD receiving IV ketamine. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
33. Antisuicidal and antidepressant effects of ketamine and esketamine in patients with baseline suicidality: A systematic review.
- Author
-
Siegel, Ashley N., Di Vincenzo, Joshua D., Brietzke, Elisa, Gill, Hartej, Rodrigues, Nelson B., Lui, Leanna M.W., Teopiz, Kayla M., Ng, Jason, Ho, Roger, McIntyre, Roger S., and Rosenblat, Joshua D.
- Subjects
- *
SUICIDAL ideation , *ATTEMPTED suicide , *KETAMINE , *ANTIDEPRESSANTS , *MENTAL depression - Abstract
Suicide accounts for approximately 800,000 deaths per year globally. Previous research has shown that intranasal esketamine and intravenous ketamine can rapidly decrease the severity of depressive symptoms and suicidal ideation. However, the majority of clinical trials excluded individuals with moderate to high baseline suicidality scores (e.g., suicidal ideation with plan/intent at the time of recruitment). The current review aims to evaluate the effect of esketamine and ketamine in patients with suicidal ideation at baseline. A systematic search was conducted on EMBASE, PsychInfo and PubMed from inception to July 2020 following the PRISMA guidelines. 15 studies met inclusion criteria. Results from esketamine trials did not demonstrate antisuicidal effects, as between-group differences were not found. Intravenous ketamine appeared to rapidly decrease the severity of suicidal ideation and depressive symptoms in individuals with baseline suicidal ideation, though retrospective studies suggest that these effects may be short-lasting. During the double-blind treatment phases, 2.4% of patients from the treatment groups and 1.5% of patients from control groups attempted suicide, with zero deaths by suicide in both the treatment and control groups during this phase. Based on the overall pooled samples, studies were assessed to be relatively safe, and the continual inclusion of this study population in future clinical trials is encouraged. Future research should aim to assess the longitudinal efficacy of ketamine in patients with baseline suicidality. • IV ketamine is associated with rapid & robust decreases in suicidal ideations. • Esketamine has antidepressant effects in patients with baseline suicidality. • The proportion of suicide attempts and death by suicide during these trials was low. • Future trials should consider including patients with baseline suicidality. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
34. Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence.
- Author
-
Lipsitz, Orly, McIntyre, Roger S., Rodrigues, Nelson B., Lee, Yena, Cha, Danielle S., Gill, Hartej, Subramaniapillai, Mehala, Kratiuk, Kevin, Lin, Kangguang, Ho, Roger, Mansur, Rodrigo B., and Rosenblat, Joshua D.
- Subjects
- *
KETAMINE abuse , *POSTMENOPAUSE , *KETAMINE , *DRUG efficacy , *POSTPARTUM depression , *SUICIDAL ideation - Abstract
Women are disproportionately represented amongst samples of adults with treatment-resistant depression (TRD). Ketamine has demonstrated rapid and robust efficacy in adults with TRD. Herein, we sought to determine whether the effectiveness of intravenous (IV) ketamine was influenced by menopausal status in women with TRD. We defined premenopausal women as those under the age of 45 (n = 52), while postmenopausal women (n = 54) were those over the age of 51. Participants received four IV ketamine infusions over one-to-two weeks at a community-based center for adults with TRD. The primary outcome of interest was the change in depressive symptom severity as measured by the Quick Inventory of Depressive Symptomatology Self-Report 16 (QIDS-SR 16) following four infusions, compared to pretreatment. The secondary outcomes were improvements in suicidal ideation (SI; i.e., QIDS-SR 16 SI item), anxiety (i.e., Generalized Anxiety Disorder-7 scale), anhedonic severity (i.e., Snaith-Hamilton Pleasure Scale), and workplace and psychosocial function (i.e., Sheehan Disability Scale). Menopausal status did not influence overall treatment response, F (4, 280) = 1.83, p =.123, η p 2 = 0.025. Both premenopausal and postmenopausal participants demonstrated similar response rates (30% and 26%, respectively) and remission rates (both 13%) to IV ketamine treatment following four infusions. Premenopausal women experienced improvements in social function more rapidly than postmenopausal women, F (2, 174) = 1.65, p =.047, η p 2 = 0.019. Postmenopausal women experienced reduction in SI more rapidly than premenopausal women, F (4, 280) = 2.72, p =.030, η p 2 = 0.037. These preliminary post-hoc findings provide the impetus for future studies to investigate the moderational role of menopausal status, as defined by hormone levels, on response to IV ketamine for TRD. • Postmenopausal women with treatment-resistant depression experienced rapid antidepressant effects with IV ketamine. • Postmenopausal women experienced anti-suicidality effects of IV ketamine more rapidly than premenopausal women. • Premenopausal women experienced improvements in social function with IV ketamine more rapidly than postmenopausal women. • Evaluation of safety and efficacy of IV ketamine for peri/postpartum depression may be warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
35. A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions.
- Author
-
Rodrigues, Nelson B., McIntyre, Roger S., Lipsitz, Orly, Lee, Yena, Cha, Danielle S., Shekotikhina, Margarita, Vinberg, Maj, Gill, Hartej, Subramaniapillai, Mehala, Kratiuk, Kevin, Lin, Kangguang, Ho, Roger, Mansur, Rodrigo B., and Rosenblat, Joshua D.
- Subjects
- *
MEDICAL personnel , *KETAMINE , *SYMPTOMS , *RANK correlation (Statistics) , *MENTAL depression , *DIAGNOSIS of dissociative disorders , *RESEARCH , *INTRAVENOUS therapy , *ANESTHETICS , *DISSOCIATIVE disorders , *RETROSPECTIVE studies , *MEDICAL cooperation , *COMPARATIVE studies - Abstract
Background: Dissociation is a treatment-emergent adverse event commonly associated with IV ketamine, often measured using the 23-item Clinician-Administered Dissociative States Scale (CADSS). The objective of this study was to develop a short form version of the CADSS for easier clinical use.Methods: Retrospective data of 260 patients with treatment-resistant depression (TRD) receiving IV ketamine were randomly divided into two datasets. The first dataset (n = 130) was leveraged to develop a brief 6-item version of the CADSS (CADSS-6) based on items most sensitive to ketamine-induced dissociation. The CADSS-6 questions were then applied to the second dataset (n = 130) and the Spearman's correlation between the full-length CADSS and the CADSS-6 were assessed.Results: The CADSS-6 was developed from questions 1, 2, 6, 7, 15, and 22 from the full length CADSS. There was a strong significant correlation between the CADSS-6 total score and the CADSS total score at infusions 1 (rs(106) = 0.92, p < 0.001), 2 (rs(100) = 0.91, p < 0.001), 3(rs(99) = 0.95, p < 0.001) and 4 (rs(102) = 0.94, p < 0.001).Limitations: The CADSS-6 was developed using a retrospective data; therefore, the scale remains unvalidated in this population.Conclusions: The CADSS-6 presented herein was sensitive to dissociation experienced by patients receiving IV ketamine. Overall, the CADSS-6 was strongly correlated at each infusion with the full-length CADSS. While future studies should look to validate the CADSS-6 in a TRD sample, this scale offers clinicians a brief assessment that can be used to characterize symptoms of dissociation. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
36. Ecological momentary assessment of depressive symptoms using the mind.me application: Convergence with the Patient Health Questionnaire-9 (PHQ-9).
- Author
-
McIntyre, Roger S., Lee, Yena, Rong, Carola, Rosenblat, Joshua D., Brietzke, Elisa, Pan, Zihang, Park, Caroline, Subramaniapillai, Mehala, Ragguett, Renee-Marie, Mansur, Rodrigo B., Lui, Leanna M.W., Nasri, Flora, Gill, Hartej, and Berriah, Said
- Subjects
- *
ECOLOGICAL momentary assessments (Clinical psychology) , *MENTAL depression , *SOCIAL networks , *COMMUNICATIVE disorders , *MENTAL illness , *DATA transmission systems - Abstract
Ecological momentary assessment (EMA) for mental disorders, using application-based (app) technology capable of passive and ambient data collection, has been insufficiently evaluated and validated with rigorous, adequately-powered, high-quality studies. Herein, we sought to validate the mind.me application for the assessment of depressive symptoms in adults. Adults (ages 18–65) who self-identified as having clinically significant depressive symptoms [i.e. Patient Health Questionnaire 9 (PHQ-9) ≥ 5] utilized the mind.me app—a mobile phone technology that collects data passively and continuously, and is capable of integrating broad multimodal data [e.g., location variance (e.g. GPS), behavioural (e.g. social network activity), and communication data (e.g. SMS texting, phone calls)]. The primary outcome was predictive accuracy (i.e. convergent validity with depressive symptom measurement, as captured by the PHQ-9). 200 subjects were enrolled in the study (mean age 46 ± 12.71). The average PHQ-9 score was 12.8 ± 6.9. The predictive accuracy of the mind.me app was 0.91 ± 0.06. The sensitivity was 0.98 and the specificity was 0.93. The mind.me app was rated by 200 users as highly usable and informative to their illness. The mind.me app exhibits robust predictive accuracy in detecting depressive symptoms in adults with clinically relevant depressive symptoms. The mind.me app more specifically demonstrates convergence with the PHQ-9. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
37. Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
- Author
-
Rodrigues, Nelson B., McIntyre, Roger S., Lipsitz, Orly, Cha, Danielle S., Lee, Yena, Gill, Hartej, Majeed, Amna, Phan, Lee, Nasri, Flora, Ho, Roger, Lin, Kangguang, Subramaniapillai, Mehala, Kratiuk, Kevin, Mansur, Rodrigo B., and Rosenblat, Joshua D.
- Subjects
- *
MENTAL depression , *SYMPTOMS , *KETAMINE , *KETAMINE abuse , *INTRAVENOUS therapy , *BODY mass index - Abstract
Background: Anhedonia is a trans-diagnostic, multidimensional phenotype that mediates patient outcomes and suicidality. Convergent evidence suggests that ketamine may be effective in targeting measures of anhedonia in adults with treatment resistant depression (TRD).Methods: This retrospective, post-hoc analysis included 203 (x̄ = 45 ± 14.6 years of age) patients receiving four infusions of intravenous (IV) ketamine at a community-based clinic. The primary outcome measure was change in anhedonia severity, as measured by the Snaith-Hamilton Pleasure Scale (SHAPS). Secondary measures sought to determine if improvement on the SHAPS mediated the effect of repeated IV ketamine infusions on symptoms of depression and suicidal ideations, as measured by the Quick Inventory for Depression Symptomatology-Self Report 16-Item (QIDS-SR16) and anxiety, as measured using the Generalized Anxiety Disorder-7 (GAD-7).Results: After adjusting for age, sex, primary diagnosis, concomitant medication, body mass index, and baseline depression severity, there was a statistically significant reduction in symptoms of anhedonia with IV ketamine treatment (F (2, 235.6) = 31.6, p < 0.001). Improvements in depressive symptoms, suicidal ideation, and anxiety symptoms with repeated-dose IV ketamine were significantly partially mediated by reduction in anhedonic severity. Moreover, the combination of number of infusions received and change in anhedonic severity accounted for 26% of the variance in depressive score improvements.Limitations: This is a post-hoc analysis of retrospective data and lacks a control group.Conclusion: Ketamine was effective in improving measures of anhedonia in this large, well-characterized community-based sample of adults with TRD. Improvements in anhedonia also partially mediated the significant improvement in depressive symptoms, suicidality, and anxiety. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
38. The utility of smartphone-based, ecological momentary assessment for depressive symptoms.
- Author
-
Yim, Samantha J., Lui, Leanna M.W., Lee, Yena, Rosenblat, Joshua D., Ragguett, Renee-Marie, Park, Caroline, Subramaniapillai, Mehala, Cao, Bing, Zhou, Aileen, Rong, Carola, Lin, Kangguang, Ho, Roger C., Coles, Alexandria S., Majeed, Amna, Wong, Elizabeth R., Phan, Lee, Nasri, Flora, and McIntyre, Roger S.
- Subjects
- *
ECOLOGICAL momentary assessments (Clinical psychology) , *SYMPTOMS , *MENTAL depression , *ONLINE databases , *AFFECTIVE disorders , *PATIENT satisfaction - Abstract
Background: Major Depressive Disorder (MDD) is a common and debilitating mood disorder. Individuals with MDD are often misdiagnosed or diagnosed in an untimely manner, exacerbating existing functional impairments. Ecological momentary assessment (EMA) involves the repeated sampling of an individual's symptoms within their natural environment and has been demonstrated to assist in illness assessment and characterization. Capturing data in this way would set the stage for improved treatment outcomes and serve as a complementary resource in the management and treatment of depressive symptoms.Methods: Online databases PubMed/MedLine and PsycINFO were searched using PRISMA guidelines and combinations of the following keywords: EMA, depression, smartphone app, diagnosing, symptoms, phone, app, ecological momentary assessment, momentary assessment, data mining, unobtrusive, passive data, GPS, sensor.Results: A total of nineteen original articles were identified using our search parameters and ten articles met the inclusion criteria for full-text review. Among the ten relevant studies, three studies evaluated feasibility, seven evaluated detection, and three evaluated treatment of MDD.Limitations: Limitations include that the design of all of the studies included in this review are non-randomized. It should be noted that most of the studies included were pilot studies and/or exploratory trials lacking a control group.Conclusions: Available evidence suggests that the use of passive smartphone-based applications may lead to improved management of depressive symptoms. This review aids the creation of new EMA applications, highlights the potential of EMA usage in clinical settings and drug development, emphasizes the importance for regulation of applications in the mental health field, and provides insight into future directions. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
39. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
- Author
-
Haikazian, Sipan, Chen-Li, David C.J., Johnson, Danica E., Fancy, Farhan, Levinta, Anastasia, Husain, M. Ishrat, Mansur, Rodrigo B., McIntyre, Roger S., and Rosenblat, Joshua D.
- Subjects
- *
MENTAL depression , *PSILOCYBIN , *CLINICAL trials , *ANIMAL-assisted therapy - Abstract
• 13 clinical trials evaluated the antidepressant effects of psilocybin. • Psilocybin consistently showed robust antidepressant effects. • Pooled remission rates were 45 % vs 22 % for psilocybin vs comparators. • All cause drop-out was comparable between groups suggesting adequate acceptability. The aim of this review was to determine the effect of psilocybin on depressive symptoms in patients diagnosed with life-threatening illnesses or major depressive disorder. Systematic searches were conducted to search for randomized clinical trials and open-label trials that evaluated depression symptoms after psilocybin therapy. Data was pooled using a random-effects model. The primary outcome was the standardized mean difference (SMD) in depression severity, determined by calculating the change in depression ratings from baseline to the primary endpoint in the psilocybin arm versus the control arm. The literature search yielded 1734 studies, and 13 studies (n = 686) were included in either qualitative and/or quantitative analyses. The meta-analysis included 9 studies (pooled n = 596) and yielded a large effect size in favour of psilocybin (SMD = -0.78; p<0.001). Risk ratios for response and remission were large and significant in favour of psilocybin. A review of open-label trials showed robust decreases in depressive symptoms following psilocybin administration. These findings provide preliminary evidence for antidepressant efficacy with psilocybin-assisted psychotherapy, however, further studies are needed to evaluate safety and efficacy and to optimize treatment protocols. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
40. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review.
- Author
-
Cao, Bing, Zhu, Judy, Zuckerman, Hannah, Rosenblat, Joshua D., Brietzke, Elisa, Pan, Zihang, Subramanieapillai, Mehala, Park, Caroline, Lee, Yena, and McIntyre, Roger S.
- Subjects
- *
MENTAL depression , *DULOXETINE , *RILUZOLE , *META-analysis , *ANHEDONIA , *EXCITATORY amino acid agents , *THERAPEUTICS - Abstract
Anhedonia is defined as a diminished ability to experience interest or pleasure, and is a critical psychopathological dimension of major depressive disorder (MDD). The purpose of the current systematic review is to evaluate the therapeutic efficacy of pharmacological treatments on measures of anhedonia in adults with MDD. Electronic databases Cochrane Library (CENTRAL), Ovid MEDLINE, PubMed, PsycINFO, and Google Scholar were searched from inception to June 1, 2018 for longitudinal studies utilizing pharmacotherapy for the treatment of anhedonia in patients with MDD. A total of 17 eligible studies were identified (i.e., evaluated the effects of pharmacotherapy on a measure of anhedonia). Among the identified studies, the efficacy of 14 different pharmacotherapies on measures of anhedonia were evaluated, including melatonergic agents (i.e. agomelatine), monoaminergic agents (i.e. moclobemide, clomipramine, bupropion, venlafaxine, fluoxetine, amitifadine and levomilnacipran, escitalopram, and sertraline), glutamatergic agents (i.e., ketamine and riluzole), stimulants (i.e., methylphenidate), and psychedelics (i.e., psilocybin). Based on the available evidence, most antidepressants demonstrated beneficial effects on measures of anhedonia as well as the other depressive symptoms. Only escitalopram/riluzole combination treatment was ineffective in treating symptoms of anhedonia in MDD. Continued research is warranted to further support the efficacy of mechanistically-distinct antidepressants in treating symptoms of anhedonia in MDD. Future research should also aim to parse out the heterogeneous effects of different pharmacotherapies on anhedonic symptoms. • Majority of antidepressants do not show pronounced collinear improvements in anhedonia and other depressive symptoms. • Therapies targeting melatonergic receptors and circadian rhythm imbalances are more direct targets for treating anhedonia. • Ketamine may be faster acting of anti-anhedonia due to direct effect on mitochondrial energy metabolism. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
41. The long-term effect of bariatric surgery on depression and anxiety.
- Author
-
Gill, Hartej, Kang, Simratdeep, Lee, Yena, Rosenblat, Joshua D., Brietzke, Elisa, Zuckerman, Hannah, and McIntyre, Roger S.
- Subjects
- *
BARIATRIC surgery , *OBESITY , *ANXIETY , *AFFECTIVE disorders , *MENTAL depression , *PSYCHOLOGY information storage & retrieval systems , *MEDLINE , *ONLINE information services , *SYSTEMATIC reviews , *MORBID obesity - Abstract
Background: No previous review has comprehensively assessed long-term changes in anxiety and depressive symptoms in bariatric surgery patients. This systematic review assessed the effects of bariatric surgery on long-term reductions (≥ 24 months) in anxiety and depressive symptom severity in morbidly obese (≥ 35 BMI kg/m2) participants. Short term effects (< 24 months) are briefly reviewed for context.Methods: PsychINFO, Google Scholar and PubMed databases were systematically searched for prospective cohort studies published from inception to 14 June 2018 that evaluated long-term (≥ 24 months) changes in anxiety and depressive symptom severity in bariatric surgery patients with a BMI ≥ 35 kg/m2 using a combination of the following search terms: bariatric surgery (and surgical approaches included under this term), obesity, depression, depressive disorder, anxiety, anxious, psychiatric disorders, mood disorders.Results: We reviewed 2058 articles for eligibility; 14 prospective studies were included in the systematic review. 13 studies (93%) reported significant reductions in depressive symptom severity 2-3 years after bariatric surgery. However, all studies recorded statistically significant reductions in depressive symptoms at the conclusion of the study. Similarly, there were reductions in overall anxiety symptom severity at ≥ 24 months follow-up (k = 8 studies, n = 1590 pooled). Pre-operative anxiety or depression scores did not predict outcomes of post-operative BMI. Similarly, post-surgery weight loss did not predict changes in anxiety symptoms.Limitations: Very few studies assessed anxiety or depression as a primary outcome. Therefore, we cannot suggest bariatric surgery as a stand-alone therapeutic tool for anxiety and depression based on our findings.Conclusion: Currently available evidence suggests that bariatric surgery is associated with long-term reductions in anxiety and depressive symptoms. This supports existing literature showing that metabolic treatments may be a viable therapeutic intervention for mood disorders. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
42. Applications of machine learning algorithms to predict therapeutic outcomes in depression: A meta-analysis and systematic review.
- Author
-
Lee, Yena, Ragguett, Renee-Marie, Mansur, Rodrigo B., Boutilier, Justin J., Rosenblat, Joshua D., Trevizol, Alisson, Brietzke, Elisa, Lin, Kangguang, Pan, Zihang, Subramaniapillai, Mehala, Chan, Timothy C.Y., Fus, Dominika, Park, Caroline, Musial, Natalie, Zuckerman, Hannah, Chen, Vincent Chin-Hung, Ho, Roger, Rong, Carola, and McIntyre, Roger S.
- Subjects
- *
MENTAL depression , *AFFECTIVE disorders , *MACHINE learning , *TREATMENT effectiveness , *BRAIN imaging , *THERAPEUTICS , *ANTIDEPRESSANTS , *DIAGNOSIS of mental depression , *ALGORITHMS , *META-analysis , *NEURORADIOLOGY , *SYSTEMATIC reviews , *RETROSPECTIVE studies , *COMPUTER-aided diagnosis - Abstract
Background: No previous study has comprehensively reviewed the application of machine learning algorithms in mood disorders populations. Herein, we qualitatively and quantitatively evaluate previous studies of machine learning-devised models that predict therapeutic outcomes in mood disorders populations.Methods: We searched Ovid MEDLINE/PubMed from inception to February 8, 2018 for relevant studies that included adults with bipolar or unipolar depression; assessed therapeutic outcomes with a pharmacological, neuromodulatory, or manual-based psychotherapeutic intervention for depression; applied a machine learning algorithm; and reported predictors of therapeutic response. A random-effects meta-analysis of proportions and meta-regression analyses were conducted.Results: We identified 639 records: 75 full-text publications were assessed for eligibility; 26 studies (n=17,499) and 20 studies (n=6325) were included in qualitative and quantitative review, respectively. Classification algorithms were able to predict therapeutic outcomes with an overall accuracy of 0.82 (95% confidence interval [CI] of [0.77, 0.87]). Pooled estimates of classification accuracy were significantly greater (p < 0.01) in models informed by multiple data types (e.g., composite of phenomenological patient features and neuroimaging or peripheral gene expression data; pooled proportion [95% CI] = 0.93[0.86, 0.97]) when compared to models with lower-dimension data types (pooledproportion=0.68[0.62,0.74]to0.85[0.81,0.88]).Limitations: Most studies were retrospective; differences in machine learning algorithms and their implementation (e.g., cross-validation, hyperparameter tuning); cannot infer importance of individual variables fed into learning algorithm.Conclusions: Machine learning algorithms provide a powerful conceptual and analytic framework capable of integrating multiple data types and sources. An integrative approach may more effectively model neurobiological components as functional modules of pathophysiology embedded within the complex, social dynamics that influence the phenomenology of mental disorders. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
43. Cognitive impairment as measured by the THINC-integrated tool (THINC-it): The association with self-reported anxiety in Major Depressive Disorder.
- Author
-
Cha, Danielle S., Carmona, Nicole E., Rodrigues, Nelson B., Mansur, Rodrigo B., Lee, Yena, Subramaniapillai, Mehala, Phan, Lee, Cha, Rebekah H., Pan, Zihang, Lee, Jae Hon, Lee, JungGoo, Almatham, Fahad, Alageel, Asem, Rosenblat, Joshua D., Shekotikhina, Margarita, Rong, Carola, Harrison, John, and McIntyre, Roger S.
- Subjects
- *
MILD cognitive impairment , *ANXIETY disorders , *MENTAL depression , *ADULTS , *DISEASE relapse , *MENTAL health - Abstract
Background and objectives This study evaluated the association between self-reported anxiety and objective/subjective measures of cognitive performance in adults with Major Depressive Disorder (MDD). Methods Acutely depressed subjects with recurrent MDD ( n = 100) and age-, sex-, and education-matched healthy controls (HC; n = 100) between the ages of 18 and 65 completed the cross-sectional validation study of the THINC-integrated tool (THINC-it; ClinicalTrials.gov: NCT02508493). Objective cognitive performance was assessed using the THINC-it, and subjective cognitive impairment with the Perceived Deficits Questionnaire for Depression–5-item. Subjects also completed the Generalized Anxiety Disorder-7-item (GAD-7) questionnaire. Results Subjects with MDD reported significantly more anxiety symptoms, as assessed by the GAD-7, compared to HC ( p < 0.001). Linear regression analysis determined that anxiety symptoms significantly accounted for 70.4% of the variability in subjective cognitive impairment, adjusting for depression severity. Moreover, subjects’ ratings of the difficulties caused by their anxiety were reported as significantly more severe among subjects with MDD when compared to HC ( p < 0.001). Likewise, greater self-reported difficulties with anxiety significantly predicted 57.8% of the variability in subjective cognitive impairment, adjusting for depression severity. Neither anxiety symptoms nor impairment due to anxiety symptoms predicted objective cognitive performance. Limitations Subjects were not prospectively verified to have a clinical diagnosis of GAD. Rather, this study examined the relationships between symptoms of generalized anxiety, assessed using a brief screening tool, and subjective and objective cognitive function. Conclusions Results from the current study indicate that adults with MDD and high levels of self-reported anxiety are significantly more likely to report experiencing subjective cognitive dysfunction. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
44. Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder.
- Author
-
Cha, Danielle S., Carmona, Nicole E., Subramaniapillai, Mehala, Mansur, Rodrigo B., Shekotikhina, Margarita, Park, Caroline, Lee, Yena, Rosenblat, Joshua D., McIntyre, Roger S., Hon Lee, Jae, Lee, JungGoo, Rong, Carola, Baune, Bernhard T., Harrison, John, Greer, Tracy L., and Lam, Raymond
- Subjects
- *
MILD cognitive impairment , *MENTAL depression , *COGNITIVE ability , *SYMPTOMS , *ANTIDEPRESSANTS , *DULOXETINE , *COGNITION disorders diagnosis , *DIAGNOSIS of mental depression , *NEUROPSYCHOLOGICAL tests , *PSYCHOLOGICAL tests , *SELF-evaluation , *SOCIAL skills , *CROSS-sectional method - Abstract
Background: Psychosocial impairment represents an important treatment target in major depressive disorder (MDD). The majority of patients with MDD do not regain premorbid levels of psychosocial functioning despite the resolution of core depressive symptoms. This study aimed to investigate the respective effects of cognitive function and depression severity on impaired psychosocial function in MDD.Methods: Adults aged 18-65 with moderate-to-severe MDD (n = 100) and age-, sex-, and education-matched healthy controls participated in a cross-sectional study validating the THINC-integrated tool (THINC-it), a cognitive screening tool comprised of objective and subjective measures of cognitive function. Depression severity was assessed using the Montgomery-Åsberg Depression Rating Scale and psychosocial function was assessed using the Sheehan Disability Scale (SDS).Results: Subjects with MDD reported greater impairment in psychosocial function than healthy controls, with significant differences in SDS total and domain scores (ps < .01) after controlling for age, sex, and education. Generalized linear models indicated that subjective cognitive function was most strongly associated with SDS total score (RR = .14, p = .01) and SDS domains of work/school (RR = .15, p = .03), family and home responsibilities (RR = .15, p = .02), and economic days lost (RR = .18, p =.03). Depression severity was most strongly associated with SDS social life (RR = .08, p < .01) and economic days underproductive (RR = .07, p < .01). Objective cognitive function was not significantly associated with any SDS outcomes.Limitations: The cross-sectional, observational study design limits temporal inferences. The self-report nature of measures included may have influenced associations observed. Potential medication effects are not noted.Conclusions: Cognitive deficits, as measured by the THINC-it, are associated with significant psychosocial impairment in MDD. These results provide empirical support for the assessment of both subjective and objective measures of cognition, as they are not associated with each other and have differential effects on functional trajectory. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
45. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder.
- Author
-
Danayan, Kevork, Chisamore, Noah, Rodrigues, Nelson B., Vincenzo, Joshua D. Di, Meshkat, Shakila, Doyle, Zoe, Mansur, Rodrigo, Phan, Lee, Fancy, Farhan, Chau, Edmond, Tabassum, Aniqa, Kratiuk, Kevin, Arekapudi, Anil, Teopiz, Kayla M., McIntyre, Roger S., and Rosenblat, Joshua D.
- Subjects
- *
BORDERLINE personality disorder , *KETAMINE , *AFFECTIVE disorders , *COMORBIDITY , *SUICIDAL ideation , *MENTAL depression - Abstract
• Comorbidity of borderline personality disorder (BPD) with depression is common. • Comorbid BPD is often associated with poorer response to antidepressants. • Ketamine was as effective for the BPD-positive sample as it was for participants without BPD. • BPD was not associated with poorer response to ketamine. • Ketamine was associated with improvements in core symptoms of BPD. Borderline personality disorder (BPD) has high rates of comorbidity with mood disorders, including treatment-resistant depression (TRD). Comorbidity of BPD with depression is associated with poorer response to antidepressants. Intravenous ketamine is a novel treatment for TRD that has not been specifically evaluated in patients with comorbid BPD. In this retrospective analysis of data collected from participants who received care at the Canadian Rapid Treatment Centre of Excellence (CRTCE; Braxia Health; ClinicalTrials.gov: NCT04209296), we evaluated the effectiveness of intravenous ketamine in a TRD population with comorbid BPD (N =100; n =50 BPD-positive compared with n =50 BPD-negative). Participants were administered four doses of intravenous ketamine (0.5-0.75mg/kg over 40 minutes) over two weeks. The primary outcome measures were changes in depressive symptom severity (as measured by Quick Inventory of Depressive Symptomatology–Self Report 16-item (QIDS-SR 16)) and borderline symptom severity (as measured by Borderline Symptom List 23-item (BSL-23)). Both BPD-positive and BPD-negative groups improved significantly on the QIDS-SR 16 , QIDS-SR 16 suicide ideation item, anxiety, and functionality scales with large effect sizes. There was no significant difference between groups. The BPD-positive group exhibited significant reduction of 0.64 on BSL-23 scores and a significant reduction of 5.95 on QIDS-SR 16 scores. Patients with TRD and comorbid BPD receiving ketamine exhibited a significant reduction in symptoms of depression, borderline personality, suicidality, and anxiety. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. Evaluating the neural substrates of effort-expenditure for reward in adults with major depressive disorder and obesity.
- Author
-
Gill, Hartej, McIntyre, Roger S., Hawco, Colin, Rodrigues, Nelson B., Gill, Barjot, DiVincenzo, Joshua D., Lieberman, Jonathan M., Marks, CéAnn A., Cha, Danielle S., Lipsitz, Orly, Nazal, Hana, Jasrai, Ashitija, Rosenblat, Joshua D., and Mansur, Rodrigo B.
- Subjects
- *
MENTAL depression , *REWARD (Psychology) , *FUNCTIONAL magnetic resonance imaging , *OVERWEIGHT children , *CAUDATE nucleus , *OBESITY , *OXYGEN consumption , *OXYGENATORS - Abstract
• MDD and obesity are comorbid conditions that are subserved by deficits in reward functioning. • Functional magnetic resonance imaging was performed in regions associated with reward behaviour. • We observed decreased activation in the left caudate in patients with increased BMI. • MDD and obesity comorbidity may exhibit deficits in cost-benefit decision making. Converging evidence has suggested that disturbances in monetary reward processing may subserve the shared biosignature between major depressive disorder (MDD) and obesity. However, there remains a paucity of studies that have evaluated the deficits in specific subcomponents of reward functioning in populations with MDD and obesity comorbidity. We evaluated the association between effort-expenditure for monetary reward and neural activation in regions associated with reward-based decision making (i.e., the caudate nucleus, anterior cingulate cortex (ACC) and hippocampus) in people with MDD and obesity comorbidity. We acquired structural and functional magnetic resonance imaging (fMRI) in 12 participants and performed a spherical region-of-interest analysis (ROI) using previously defined peak MNI coordinates. A one-sample t -test was employed to compare ROI-specific blood-oxygen-level-dependent (BOLD) signal change during the task choice selection window (i.e., high-effort vs. low-effort task) of the effort-expenditure for reward task (EEfRT). We observed no change in activation of the caudate nucleus, ACC or hippocampus in participants with increased BMI when contrasting the high effort > low effort reward magnitude condition for the EEfRT. The findings from our exploratory study evaluated the disturbances in fundamental reward processes, including cost-benefit decision making, in people MDD and obesity. Future studies should further investigate this relationship with a larger sample size. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
47. The Prevalence of Suicidal Behaviour in Fibromyalgia Patients.
- Author
-
Gill, Hartej, Perez, Carlos D., Gill, Barjot, El-Halabi, Sabine, Lee, Yena, Lipsitz, Orly, Park, Caroline, Mansur, Rodrigo B., Rodrigues, Nelson B., McIntyre, Roger S., and Rosenblat, Joshua D.
- Subjects
- *
FIBROMYALGIA , *ATTEMPTED suicide , *BEHAVIORAL assessment , *SUICIDAL ideation , *CHRONIC pain , *MENTAL illness , *DIALECTICAL behavior therapy - Abstract
Fibromyalgia (FM) is a condition associated with chronic pain in muscles and soft tissues. Extant literature has demonstrated an association between FM, mood symptoms and suicidal behaviour. This systematic review aims to synthesize available literature assessing the prevalence of suicidality in FM populations and qualitatively review the included articles. PsycINFO, Google Scholar and PubMed databases were systematically searched for studies published from database inception to 15 February 2020. Studies were included that assessed FM as a primary or co-primary disease condition, as well as an assessment of suicidal behaviour (suicidal ideations (SI), suicide attempts (SA) and death by suicide (SC)). The quality of the studies was assessed using the Newcastle-Ottawa Scale. 699 unique articles were reviewed for eligibility. Data were derived from nine studies (cross-sectional: k = 5; retrospective cohort: k = 4) that assessed suicidal behaviour in FM participants (SI: k = 5, SC: k = 3, SA: k = 3). Four studies assessing SI found elevated rates of SI among FM participants. Three studies found elevated risk for SC and three studies found increased SA in FM participants relative to the general population. In two studies, this association was no longer significant after adjusting for depression and other psychiatric comorbidities. Preliminary findings suggest that FM is associated with significantly higher risks for SI, SA and SC compared to the general population. There may be unique risk factors underlying suicidal behaviour in FM patients and the interaction between FM and other known risk factors (i.e., mental illness) require further investigation. • Fibromyalgia participants are at an increased risk of attempting suicide. • Suicidal ideation is elevated among participants with fibromyalgia. • Suicide mortality rates are higher in fibromyalgia than the general population. • Depression is highly comorbid with fibromyalgia. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
48. The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence.
- Author
-
Rodrigues, Nelson B., McIntyre, Roger S., Lipsitz, Orly, Lee, Yena, Subramaniapillai, Mehala, Kratiuk, Kevin, Majeed, Amna, Nasri, Flora, Gill, Hartej, Mansur, Rodrigo B., and Rosenblat, Joshua D.
- Subjects
- *
MENTAL depression , *ADULTS , *KETAMINE - Abstract
• Following 6 ketamine infusions, patients reported 2 more days of productivity. • Following 6 ketamine infusions, patients reported 1.5 less days absent from work. • Reduction in presenteeism was sustained following 5 months of ketamine infusions. • Patients exhibited sustained antidepressant effect following 5 months of IV ketamine. Numerous clinical trials have reported that intravenous (IV) ketamine demonstrates rapid antidepressant and anti-suicidal effects in patients with treatment-resistant depression (TRD). These studies, however, have not characterized whether these antidepressant effects translate to improvements in workplace productivity and functionality. Adults with TRD received repeated doses of IV ketamine at a community-based clinic (n = 171). We evaluated patient outcomes at two timepoints of interest: (1) acute-phase (i.e., following 4–6 infusions, 17.6 ± 12.6 days from baseline) and (2) maintenance-phase (i.e., following 7–10 infusions, 153.9 ± 63.4 days from baseline). The primary outcome measure was change from baseline to maintenance-phase scores on the Sheehan Disability Scale (SDS) workplace/school item as well as days underproductive (i.e., presenteeism) and days lost (i.e., absenteeism). Secondary measures included the Quick Inventory for Depression Symptomatology-Self Report 16-Item (QIDS-SR 16). There was a significant reduction in workplace/school disability, and significantly reduced symptoms of presenteeism and absenteeism. At the acute-phase outcome, this translated to 2 more days of productivity and 1.5 less days absent from work. Additionally, IV ketamine exhibited a sustained antidepressant effect across the ten infusions. IV ketamine was associated with a significant reduction in workplace/school disability and demonstrated improvements in symptoms of presenteeism and absenteeism. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
49. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
- Author
-
Lipsitz, Orly, McIntyre, Roger S., Rodrigues, Nelson B., Kaster, Tyler S., Cha, Danielle S., Brietzke, Elisa, Gill, Hartej, Nasri, Flora, Lin, Kangguang, Subramaniapillai, Mehala, Kratiuk, Kevin, Teopiz, Kayla, Lui, Leanna M.W., Lee, Yena, Ho, Roger, Shekotikhina, Margarita, Mansur, Rodrigo B., and Rosenblat, Joshua D.
- Subjects
- *
MENTAL depression , *KETAMINE , *MONOAMINE transporters , *SYMPTOMS , *DRUG infusion pumps - Abstract
Early symptomatic improvement with monoamine-based antidepressants is predictive of treatment response. The objective of this study was to determine if early symptomatic improvements with intravenous (IV) ketamine predicted treatment response to an acute course of four infusions. 134 adults with treatment resistant depression (TRD) received four ketamine infusions over one to two weeks. Depressive symptoms were measured using the Quick Inventory for Depressive Symptomatology Self-Report 16 (QIDS-SR 16) at baseline and post-infusions 1, 2, 3, and 4. Early improvement was defined as ≥20% reduction in QIDS-SR 16 scores after the first or second infusion. Linear models were used to determine whether early improvement was associated with post-infusion 4 QIDS-SR 16 scores after controlling for baseline characteristics. Early improvement post-infusion 1 (β = −3.52, 95% BCa CI [−5.40, −1.78]) and 2 (β = −3.16, 95% BCa CI [−5.75, −1.59]) both significantly predicted QIDS-SR 16 scores post-infusion 4. Early improvers had significantly lower QIDS-SR 16 scores at post-infusion 4 (post-infusion 1 improvers: M = 9.8, SD = 4.5; post-infusion 2 improvers: M = 10.6, SD = 5.7) compared to non-early improvers (post-infusion 1 non-improvers: M = 13.7, SD = 5.8; post-infusion 2 non-improvers: M = 14.1, SD = 5.3) when controlling for baseline characteristics. The majority (58%) of individuals who did not improve post-infusions 1 or 2 still experienced an antidepressant response or partial response (≥20% reduction in QIDS-SR 16) post-infusion 4. This is a post-hoc analysis of an open-label study. Early improvement was associated with greater antidepressant effects following a course of four ketamine infusions. However, individuals who did not show early improvements still had a high likelihood of experiencing clinically significant symptom reduction after the fourth infusion, suggesting that completing four infusions, regardless of early symptom changes, is appropriate and merited. • Early symptom improvement was associated with greater antidepressant effects following four ketamine infusions. • ~40% of individuals with early improvement responded to the full treatment course versus 14–19% in non-early improvers. • 58% of individuals who did not experience early improvement experienced a partial to full response after the fourth infusion. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
50. Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatment.
- Author
-
Siegel, Ashley N., Rodrigues, Nelson, Nasri, Flora, Wilkialis, Linas, Lipsitz, Orly, Lee, Yena, Gill, Hartej, Subramaniapillai, Mehala, Phan, Lee, Majeed, Amna, Lui, Leanna M.W., Rashidian, Houman, Ho, Roger, Toma, Simina, Goldstein, Benjamin I., Mansur, Rodrigo B., McIntyre, Roger S., and Rosenblat, Joshua D.
- Subjects
- *
AFFECTIVE disorders , *PENTOXIFYLLINE , *MENTAL depression , *PHOSPHODIESTERASE inhibitors , *BIPOLAR disorder - Abstract
Numerous pharmacological treatments for mood disorders are currently available; however, rates of treatment resistance, relapse and recurrence remain high. Therefore, novel treatments acting outside of the conventionally targeted monoamine system are urgently needed to improve patient outcomes. Emerging and converging evidence suggests that immune dysfunction, oxidative stress, impaired cerebral blood flow (CBF) and decreased neurotrophic factors all contribute to mood disorder pathophysiology and are therefore treatment targets of interest. Pentoxifylline (PTX) is a phosphodiesterase inhibitor with potent anti-inflammatory and antioxidant effects, with additional pleiotropic effects that lead to improved CBF and increases in brain derived neurotrophic factor (BDNF) levels. The direct effect of non-specific phosphodiesterase inhibition may also improve alertness and cognitive function through enhancing second messenger systems. Replicated preclinical studies have demonstrated antidepressant-like effects in animal models. Small preliminary clinical trials have demonstrated promising results for antidepressant and procognitive effects, however, have yet to be replicated in larger mood disorder samples. Only one randomized clinical trial (RCT) specifically assessed the effects of adjunctive PTX in major depressive disorder (MDD), showing clinically and statistically significant antidepressant effects compared to placebo. No studies have assessed PTX in bipolar disorder (BD), where inflammation and altered CBF have also been strongly implicated. Taken together, PTX presents as a promising pleiotropic agent with several potential novel mechanisms of action meriting further evaluation in clinical trials to evaluate target engagement, antidepressant, procognitive and mood stabilizing effects. • Immune dysfunction, oxidative stress and impaired cerebral blood flow are observed in mood disorders • Pentoxifylline (PTX) is a phosphodiesterase inhibitor with anti-inflammatory, antioxidant, and neurotrophic effects • PTX may improve cerebral blood flow • Preclinical and preliminary clinical data suggests that PTX may have antidepressant properties [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.